Search Results - "Rajasekera, P."

Biochemical and Biophysical Studies of Novel Small Molecules Targeting Proteasome Subunit Alpha Type-7 (PSMA7) for the Treatment of Glioblastoma by Showalter, C.A., Rajasekera, P., Kumar, A., Singh, K., Biehn, S., Pérez-Soto, B., Lindert, S., Manring, H., Haque, S.J., Chakravarti, A.

“…Glioblastoma (GBM) is the most common and aggressive primary brain tumor with less than 10% of patients surviving beyond 5 years after diagnosis. Even when…”
Get full text

Identification and Validation of Proteasome Subunit Alpha Type-7 (PSMA7) as a Therapeutically Vulnerable Target in GBM by Showalter, C.A., Cui, T., Sebastian, E., Rajasekera, P., McElroy, J., Becker, A., Fleming, J.L., Manring, H., Haque, S.J., Chakravarti, A.

Get full text

PO-2218 RNAi-mediated silencing of PSMA7 sensitizes GBM cells to ionizing radiation and temozolomide by Showalter, C., Cui, T., Sebastian, E., Rajasekera, P., McElroy, J., Becker, A., Fleming, J., Manring, H., Haque, S.J., Chakravarti, A.

Get full text

In Silico Discovery and Investigation of Novel Small Molecules Targeting PSMA7 for the Treatment of GBM by Showalter, C.A., Rajasekera, P., Biehn, S., Pérez-Soto, B., Lindert, S., Bennett, C., McElroy, J., Manring, H., Haque, S.J., Chakravarti, A.

“…The five-year survival rate for glioblastoma (GBM; WHO grade 4) remains only 5%, even with the current standard treatment of maximal safe surgical tumor…”
Get full text

Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3β Pathway in Glioblastoma by Kumar, A., Rajasekera, P., Becker, V., Biehn, S., Pérez-Soto, B., Beyer, S., McElroy, J., Becker, A., Johnson, B., Cui, T., Sebastian, E., Grosu, A., Lindert, S., Bell, E.H., Manring, H., Haque, J., Chakravarti, A.

“…Glioblastoma (GBM) patients with wild-type IDH experience worse survival response to the standard treatment of surgery followed by radiation therapy (RT) and…”
Get full text

Small Molecule Inhibitors Targeting Transgelin-2-Actin Interaction for Therapeutic Intervention in Glioblastoma by Kumar, A., Rajasekera, P., Becker, V., Biehn, S., Beyer, S., McElroy, J., Becker, A., Johnson, B., Cui, T., Sebastian, E., Grosu, A., Lindert, S., Bell, E.H., Manring, H., Haque, S.J., Chakravarti, A.

Get full text

PO-1145 Targeting Transgelin-2 by novel small molecule inhibitors to circumvent resistance in glioblastoma by Kumar, A., Rajasekera, P., Becker, V., Biehn, S., Beyer, S., McElroy, J., Becker, A., Johnson, B., Cui, T., Grosu, A., Lindert, S., Bell, E., Manring, H., Haque, J., Chakravarti, A.

Get full text

Pharmacological Targeting Of Transgelin-2 As A Novel Strategy Of Therapeutic Intervention In Glioblastoma by Kumar, A., Rajasekera, P., Beyer, S., McElroy, J., Grosu, A., Biehn, S., Cui, T., Becker, A., Johnson, B., Sebastian, E., Lindert, S., Bell, E.H., Haque, S.J., Chakravarti, A.

Get full text

In-Silico Discovery of Novel Small-Molecule Inhibitors Targeting Transgelin-2-Actin Interaction Inhibits Proliferation, Invasion and Improves Chemo-Radiation Response in Human Glioblastoma by Kumar, A., Rajasekera, P., Biehn, S., Beyer, S., McElroy, J., Becker, A., Johnson, B., Cui, T., Sebastian, E., Grosu, A., Lindert, S., Bell, E.H., Haque, S.J., Chakravarti, A.

“…Transgelin-2 (TAGLN2) is an oncogene and actin-binding protein known to induce actin polymerization, thereby playing a critical role in cell proliferation,…”
Get full text

Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo by Wei, Min, Marino, Jose, Trowell, Aaron, Zhang, Huiping, Stromp Peraino, Jaclyn, Rajasekera, Priyani V., Madsen, Joren C., Sachs, David H., Huang, Christene A., Benichou, Gilles, Wang, Zhirui

“…Regulatory T cells (Tregs) are a subpopulation of CD4+ T cells which suppress immune responses of effector cells and are known to play a very important role in…”
Get full text